Navigation Links
Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW

y for Surgery of the Alimentary Tract, DDW takes place May 19-24, 2007, at the Washington Convention Center, Washington, DC. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit http://www.ddw.org.

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward- looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to the impact of those on Shire's Attention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval dates of SPD503 (guanfacine extended release) (ADHD) and SPD465 (extended release triple-bead mixed amphetamine salts) (ADHD); Shire's ability to secure new products for commercialization and/or development; Shire's ability to benefit from its acquisition of New River Pharmaceuticals, Inc.; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2006.

LIALDA(TM) is a trademark of Shire LLC.

MMX(TM) is a trademark owned by Cosmo Technologies Ltd, Ireland, a wholly- owned subsidiary of Cosmo Pharmaceuticals SpA
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
3. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
4. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
5. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
6. Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
7. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
8. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
9. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
10. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
11. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
Post Your Comments:
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today issued the following open letter to shareholders ... Dr. Med. Sc. Dear RXi Shareholders, ... number of inaccurate statements posted on certain social ...
(Date:12/22/2014)... Calif. , Dec, 22, 2014  Eiger ... Phase 2a study of lonafarnib in patients with ... was conducted at the National Institutes of Health ... .  The double-blinded, randomized, placebo-controlled, dose ascending ... twice daily and 200 mg twice daily for ...
(Date:12/22/2014)... , Dec. 22, 2014  Relmada Therapeutics, Inc. ... for the treatment of chronic pain, announced today ... dosed in a pharmacokinetic and pharmacodynamic study with ... neuropathic pain. Racemic methadone is a ... pain states and substitution therapy in opioid addiction.  ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
... DATATRAK International, Inc. (OTCQX: DATA), a technology and ... clinical trials industry, today announced its attendance at the ... be held in Chicago, Illinois June 19th-23rd. ... #735 on June 20th-22nd. Individuals attending the meeting are ...
... SAN DIEGO, June 10, 2011 Gen-Probe Incorporated (NASDAQ: ... at the William Blair & Company 31st Annual Growth Stock ... p.m. Central Time (5 p.m. Eastern Time).  The presentation is ... a link on the investors section of Gen-Probe,s website at ...
Cached Medicine Technology:DATATRAK Exhibiting at 47th Annual DIA Meeting 2Gen-Probe to Webcast Presentation at the William Blair & Company 31st Annual Growth Stock Conference 2
(Date:12/24/2014)... (HealthDay News) -- Long-term fear of terrorists may damage your ... new study from Israel suggests. , , Conducted by researchers ... Israelis. In Israel, the threat of war and terrorism has ... "We wanted to test whether fear of terrorism can ... death," study author Hermona Soreq, a professor of molecular neuroscience, ...
(Date:12/24/2014)... 2014 (HealthDay News) -- If you are a high-risk ... are not treated by a cardiologist, new research suggests. ... cardiologists left town for annual professional meetings, Harvard researchers ... who were admitted to a teaching hospital during one ... percent died when these meetings were not taking place. ...
(Date:12/22/2014)... As early as thirty, gravity begins to ... form of “jowls." The dreaded droopiness usually appears around ... line or smile lines. Aging can be fought with ... the deep facial tissues descend, jowls inevitably appear. , ... can be used under the skin to fill natural ...
(Date:12/22/2014)... Sagacious Consultants, the premier full-service Epic ... to their ad hoc report writing service to meet ... sign up for an annual subscription and get a ... a deeply discounted hourly rate. , Customers can ... progressively discounted rate. Subscription hours are contracted in 25 ...
(Date:12/22/2014)... York, New York (PRWEB) December 22, 2014 ... are a staple of the season. Many may be thinking ... in a span of a few weeks. Health Republic Insurance ... help of Registered Dietitian, Andrea Chernus, to provide some smart ... eat and stay healthy. , 1)    Avoid arriving at a holiday ...
Breaking Medicine News(10 mins):Health News:Terrorism Fears May Shorten Your Life, Study Finds 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 3Health News:Sam Rizk, MD, FACS, Introduces Rapid Recovery Facelift 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:Health Republic Insurance of New York Offers Five Simple Tips to Eat Healthy During the Holidays 2
... of metabolic protein architecture and their advance offers ... ,,Researchers at the University of Illinois ... online edition of the Proceedings of the National Academy ... techniques of phylogenetic analysis developed in the past decade ...
... that it has a mix of properties that would ... matrix with metallic clusters that can absorb light, ... and then destroy those targeted cells with a laser. ... nanocomposite (DNC) matrix containing silver clusters that can be ...
... recently identified genetic marker for prostate cancer is linked ... ,These findings ultimately will aid the development ... susceptible to this aggressive cancer, Northwestern researchers said. Knowing ... doctors in how they treat the cancer. ...
... at Nokia have developed software that transforms a cellphone into ... lightning strike. ,A lightning bolt is an ... frequencies between 10 hertz and five gigahertz. However, the distribution ... is. ,According to the scientists, the multiple receivers ...
... toxic substance, made by certain types of bacteria found in house ... condition eczema or wheezing in children if they are exposed to ... Endotoxin is an element of the cell wall of gram-negative bacteria, ... when the bacteria dies or is damaged. ,The new ...
... The Most Powerful Weight-Loss Formula on Earth!" ... common in many parts of the world and thousands of ... is that there are few regulations to govern this booming ... ones that exist. ,Weight loss is a desperate ...
Cached Medicine News:Health News:Protein Folds Research Offers Insight into Metabolic Evolution 2Health News:Protein Folds Research Offers Insight into Metabolic Evolution 3Health News:Nanocomposite Labeled Cancer Cells Targeted and Destroyed by Using Lasers 2Health News:Genetic Marker Linked to Aggressive Prostate Cancer 2Health News:Beware Weight Loss Drugs, Say Canadian Experts 2Health News:Beware Weight Loss Drugs, Say Canadian Experts 3Health News:Beware Weight Loss Drugs, Say Canadian Experts 4
Cable connections for 5 different adapters: Storz, ACMI, Pentax, Wolf and Olympus....
Lightweight PVC housing for easy transport, integrated handle. Easy lamp exchange....
... in determining functionality of a patient's ... courses of treatment for patients receiving ... and autoimmune dieseases. Kit 030 ... diseases giving rise to high titers ...
Maximum brightness, durability, universal power suply, microprocessor-controlled light output and, in the event of lamp failure or degredation, automatic switchover to an integraged spare lamp....
Medicine Products: